Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression

Michihide Tokuhira, Shuntaro Saito, Ayumi Okuyama, Katsuya Suzuki, Morihiro Higashi, Shuji Momose, Takayuki Shimizu, Takehiko Mori, Tomoe Anan-Nemoto, Koichi Amano, Shinichiro Okamoto, Tsutomu Takeuchi, Jun Ichi Tamaru, Masahiro Kizaki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although recent accumulative data reveal the clinicopathogenesis of regression in methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding including this category remains controversial. In this study, we analyzed 62 patients with MTX-LPD. Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively). Among the 43 patients of the Reg group, 14 patients (33%) relapsed. The median duration before relapse in the Reg group was 10.6 months. Although the difference of OS between the Reg and Non-Reg groups was not significantly different, relapse-free patients in the Reg group had a superior overall survival (OS). MTX duration had a significant impact on Epstein–Barr virus (EBV) infection (p = .00131). Furthermore, EBV infection was significantly related to clinical manifestations, including spleen invasion, in the regression phenomenon. Some human leukocyte antigens (HLA) alleles might affect MTX-LPD development via EBV infection, although A*2402 and DRB1*0405 might be affected as fundamental factors.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 2017 Sep 7

    Fingerprint

Keywords

  • autoimmune diseases
  • lymphoproliferative disorders
  • Methotrexate
  • regression
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this